『ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline』のカバーアート

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipelineに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。